{"id":35606,"date":"2026-03-20T10:02:14","date_gmt":"2026-03-20T10:02:14","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/35606\/"},"modified":"2026-03-20T10:02:14","modified_gmt":"2026-03-20T10:02:14","slug":"novartis-expands-cancer-drug-portfolio-with-3-billion-acquisition","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/35606\/","title":{"rendered":"Novartis Expands Cancer Drug Portfolio with $3 Billion Acquisition"},"content":{"rendered":"<p>&#13;<\/p>\n<p>In a strategic move to bolster its cancer medication offerings, Novartis has entered into a definitive agreement to acquire SNV4818, a pioneering cancer drug candidate, from Synnovation Therapeutics.<\/p>\n<p>The acquisition deal, worth up to $3 billion, involves a $2 billion initial payment, with an additional $1 billion contingent on development milestones.<\/p>\n<p>The drug, a selective PI3K\u03b1 inhibitor, is currently being evaluated in early-stage trials, showing promise against mutated forms of the enzyme associated with breast and other solid tumors. Novartis&#8217; Chief Medical Officer, Shreeram Aradhye, emphasized the drug&#8217;s potential for achieving effective cancer pathway inhibition while minimizing side effects.<\/p>\n<p>&#13;<\/p>\n<p>(With inputs from agencies.)<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; In a strategic move to bolster its cancer medication offerings, Novartis has entered into a definitive agreement&hellip;\n","protected":false},"author":2,"featured_media":35607,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[207,9068,9388,21074,206,21075,21017,21015,21016,13889],"class_list":{"0":"post-35606","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-breast-cancer","9":"tag-cancer-therapy","10":"tag-cancer-treatment","11":"tag-drug-acquisition","12":"tag-novartis","13":"tag-pharmaceutical-deal","14":"tag-pi3k-inhibitors","15":"tag-snv4818","16":"tag-synnovation-therapeutics","17":"tag-targeted-therapy"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116260932622676343","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/35606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=35606"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/35606\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/35607"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=35606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=35606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=35606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}